The Over-55 Boom Is Rewriting Cannabis Dosing

Photo by RDNE Stock project via Pexels.

Nearly 22% of Americans ages 55 to 65 used cannabis in the past year, according to the 2026 Monitoring the Future report. It is the highest share that survey has recorded for the group. Adults 35 to 50, meanwhile, held flat at about 30%.

The headline is growth, but the more useful question is what this group will buy. Most of the cannabis market was built around potency-chasing flower and high-THC vapes, products designed with a 25-year-old in mind. A 62-year-old with knee pain, poor sleep and a medicine cabinet full of prescriptions is a different customer.

This piece tries to keep three kinds of statement apart: what the data shows, what is reasoned extrapolation, and what is open speculation. I will label the shifts. One caveat up front: sales data on older buyers is thin. I could not verify dispensary format shares for the over-55 segment, so anything about what is on the shelf is inference from surveys, not from the register.

What the 2026 data actually shows

Photo by cottonbro studio via Pexels.

Start with fact. Monitoring the Future, run by the University of Michigan, found nearly 22% of adults 55 to 65 used cannabis in the past 12 months. About 15% reported use in the past 30 days, and 4% reported using hemp-derived products. NORML published its write-up of the findings on August 19, 2026.

The comparison group tells the story. Adults 35 to 50 held steady near 30% past-year use, with just over 20% using in the past month and 8.5% using daily or near-daily, per Greenstate's summary. So the middle-aged group has plateaued at a high level, while the older group is still climbing from a lower base.

One claim needs careful handling. The University of Utah Health says cannabis use among adults over 60 is growing faster than in any other demographic. That is the university's own statement, as reported by ABC4, not an independent finding, and I would not lean on it harder than that.

Now the reasoned extrapolation. People who are 55 to 65 today came of age in the late 1970s, when teen cannabis use in national surveys peaked. Part of the rise may be a cohort effect: people who tried it young, drifted away, and are returning, rather than total newcomers. If that holds, the pool of likely users keeps growing as that cohort ages, because it is simply a larger share of each older age band.

The counter-case deserves equal weight. These are self-reported surveys, and stigma shifts can change how willing people are to answer honestly. The 35-to-50 plateau shows that a rise can stall. And I could not verify any sales data confirming the trend at the register, so survey growth and retail growth are not yet shown to be the same thing.

My read: the survey trend is real enough to plan around, but the size of the commercial opportunity is unproven.

What older first-time buyers say they want

Photo by Kindel Media via Pexels.

The best window into what older buyers want is a University of Utah Health and CU Boulder study released May 8, 2026. Researchers interviewed 169 adults age 60 or older in the Boulder/Denver area. All were about to buy cannabis, mostly edibles, for the first time. Rebecca Delaney, PhD, an assistant professor of population health sciences at U of U Health, led the work.

The goals were about daily life, not intoxication. Participants wanted less pain, better sleep and more enjoyment of time with family and friends. Delaney's summary was that most of these people were not interested in getting high.

The numbers back that up:

• 32% wanted edibles as an alternative to medication.
• Nearly 24% hoped edibles would help with age-related health problems.
• Nearly 29% favored mostly-CBD edibles.
• Nearly 14% wanted THC-only edibles.

That CBD-versus-THC split is the most commercially interesting line. Mostly-CBD interest ran at roughly twice the THC-only figure, in a market where THC percentage is usually the headline selling point.

Guidance was informal. Many participants relied on word of mouth from friends or family rather than health care providers. The authors suggested that providers may need better informational materials, which is a polite way of saying clinicians are not yet the trusted source.

The limits are real. The sample comes from Colorado, a legal recreational market, and the authors note that choices may differ in medical-only states such as Utah. People who walk into a Boulder dispensary are also self-selected. And these were interviews before purchase: they capture intentions, not what happened after the first gummy. Whether the pain relief, sleep gains and family time arrived is a separate question this study does not answer.

Edibles lead, but inhalation hasn't gone away

Among older adults, edibles are the most commonly reported cannabis product at 7.4% of respondents ages 55-65, well ahead of vaping (4.2%) and hemp-derived products (4%).

Edibles look like the front door for cautious older users, though the evidence is patchy. Greenstate reports that 7.4% of adults 55 to 65 consumed edibles and 4.2% vaped. The summary does not say whether those figures are past-year or past-30-day, and the data do not give a full breakdown of how older adults consume. Treat them as a rough ordering, not a precise split.

Because the time frames may differ, comparing across rows is risky. Even so, edibles outrank vaping in the same age group.

Older veterans give a second lens. A JAMA Network Open cross-sectional study, dated roughly 2025 (verify the exact publication date), surveyed 4,503 respondents. Of those, 1,193 (10.3%) used cannabis in the past 30 days, and 21.7% of past-30-day users used edibles only.

The same paper carries a warning sign. Among respondents who used any inhaled cannabis, 61.0% reported daily or near-daily use. Of 3,409 respondents with lifetime-form data, including topicals, 28.9% reported any medical use. That splits into 16.7% using for both medical and recreational purposes and 12.3% using medicinally only.

Here is my reading, and it is a reading, not a proven pattern. Edibles appear to be the entry format for cautious older newcomers, while inhaled use skews toward heavy, habitual users. The veteran data is a different population from Colorado first-timers, and it cannot tell us whether habitual smokers started that way or drifted into it.

If the interpretation is right, the market is splitting into two older consumers: a low-frequency, low-dose edible user, and a long-time inhaler who looks a lot like the established core customer.

Where dosing formats are likely heading

Photo by CBD-Infos-com via Pixabay.

Now the forecast, with its anchor stated. If the Utah/CU preferences hold, with mostly-CBD edibles outpolling THC-only at roughly 29% versus 14%, expect more shelf space for low-dose, CBD-forward or balanced-ratio products. I have no dispensary sales data on formats for this age group, so this is inference from stated intentions.

Three formats look plausible, though none is confirmed demand:

• Low-dose gummies and mints. Small, familiar, easy to split. The mechanism is simple: a smaller unit lowers the cost of a mistake.
• Tinctures and sublingual sprays. A graduated dropper lets a user adjust by a few drops. That suits people who want to find a minimum effective dose.
• Topicals. For localized joint pain, a cream or balm is attractive because it aims to work where applied rather than throughout the body.

The delayed-onset problem is the design challenge. Edibles take well over thirty minutes and sometimes up to two hours to act, which invites re-dosing by impatient users. A format built for cautious customers would address that with fast-onset sublingual or nano-emulsified products. Treat that technology claim skeptically until independent data exists on onset and consistency.

A safety caveat belongs here, and it should be verified against a primary clinical source before anyone acts on it. THC and CBD are processed by liver enzymes that also handle many common prescription drugs. Interaction questions therefore loom larger for older people taking several medications. The brief has no emergency-visit data on older adults and edibles, so I cannot size the risk.

The counter-case is straightforward. Manufacturers could keep selling high-potency products to the core market, and low-dose lines have historically been niche. What would change that is sustained retail demand from this group, visible in sales rather than surveys. Until it shows up, low-dose is a hypothesis about shelves, not a fact about them.

The information gap is the business opportunity

The documented gap is simple. Study participants leaned on word of mouth over health care providers, and the authors flagged a need for provider-facing materials. That much is fact. What fills the gap is speculation, and I will say so as I go.

Plausible opportunities, offered as ideas rather than existing market data:

• Budtender training oriented toward older customers, including medication questions and when to refer to a clinician.
• Large-print labeling with clear per-serving milligram doses.
• Clinician-facing dosing guides that a physician can hand to a patient.
• Pharmacy-style consultation areas inside dispensaries.

There is precedent to reason from, though it is an analogy and not a documented trend. Medical-program states built physician-recommendation systems early. Adult-use markets later shifted toward lifestyle branding and potency. Older consumers may pull parts of the market back toward guidance-led retail, the way medical-first states once operated.

Hemp fits here too. 4% of older respondents reported using hemp-derived products, and hemp retail often has lower barriers to entry for cautious shoppers who do not want a dispensary visit. I found nothing on hemp legislation, so I will not assert any outcome there.

The risk is overselling the evidence. Advocacy groups such as NORML cite studies linking cannabis to quality-of-life gains and reduced prescription drug use among seniors. That is advocacy framing and should be read as such. NORML also points to a Journal of Primary Care & Community Health finding that most older adults hold positive perceptions of cannabis. That shows attitudes, not clinical outcomes.

A business that markets guidance but outruns the evidence on benefits would be building trust on sand. The strongest version of this opportunity sells clarity about dose and risk, not promises about results.

What could stall the boom by 2032

Start with what I could not verify. The brief found nothing on federal rescheduling, Medicare coverage, or state medical programs for seniors. These are open and must be checked against current primary sources. Coverage is the lever most likely to move older consumers at scale, because many older buyers are cost-sensitive and used to having medicines reimbursed.

History offers a pattern. Legalization spread state by state over decades, with medical programs usually coming first. Reasoned extrapolation: older-adult access will probably track the state patchwork more than any single federal act. Medical-only states may see different product choices than Colorado, as the study authors themselves note.

For the 3-to-7-year window, I see three scenarios:

• Base case: steady growth in non-inhaled, lower-dose formats, led by edibles, tinctures and topicals.
• Upside: clinician-integrated products and dosing guidance, if outcome evidence matures.
• Downside: a plateau like the one the 35-to-50 group showed, or a safety scare involving edibles and older adults that chills demand.

Three signals would tell us which path we are on:

1. Format-level sales data for the over-55 group.
2. Emergency-department data on older adults and edibles.
3. Follow-up outcome studies on the Colorado cohort.

A limits note to close the section. The 2026 survey data is a snapshot, and every number here comes from a handful of sources. Treat the forecast as a hypothesis to test by 2032, not a schedule.

The most defensible bet is not that older people will use more cannabis, though the survey trend points that way. It is that the products they choose will look different: lower dose, less smoke, more guidance. That follows from what first-time buyers say they want and from how the veteran data separates edible users from habitual inhalers.

The weakest link is evidence on what older buyers actually purchase and how they fare afterward. Intentions before purchase are not outcomes, and survey prevalence is not sales. Whoever collects that data first, whether retailers, researchers or clinicians, will shape the market more than any single product launch.

Browse our seed collection.